



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/538,687	04/18/2006	Adeela Kamal	10608.0016-01000	3645
65779	7590	12/07/2009	EXAMINER	
BIOGEN IDEC / FINNEGAN HENDERSON, LLP 901 NEW YORK AVENUE, NW WASHINGTON, DC 20001-4413				JONES, DAMERON LEVEST
ART UNIT		PAPER NUMBER		
1618				
NOTIFICATION DATE			DELIVERY MODE	
12/07/2009			ELECTRONIC	

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

Lauren.Stevens@finnegan.com  
Regional-Desk@finnegan.com

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/538,687	KAMAL ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	D L. Jones	1618	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) Responsive to communication(s) filed on \_\_\_\_.
- 2a) This action is **FINAL**.                    2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) Claim(s) 1-12, 15, 16 and 29 is/are pending in the application.
  - 4a) Of the above claim(s) \_\_\_\_ is/are withdrawn from consideration.
- 5) Claim(s) \_\_\_\_ is/are allowed.
- 6) Claim(s) \_\_\_\_ is/are rejected.
- 7) Claim(s) \_\_\_\_ is/are objected to.
- 8) Claim(s) 1-12, 15, 16, and 29 are subject to restriction and/or election requirement.

#### Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on \_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.
 

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
  - a) All    b) Some \* c) None of:
    1. Certified copies of the priority documents have been received.
    2. Certified copies of the priority documents have been received in Application No. \_\_\_\_.
    3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)                     | 4) <input type="checkbox"/> Interview Summary (PTO-413)           |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. ____ .                                     |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)          | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date ____ .   | 6) <input type="checkbox"/> Other: ____ .                         |

## **RESTRICTION INTO GROUPS**

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

**Group (1)**, claim(s) 1-12 (all claims in part), drawn to compositions comprising purines.

**Group (2)**, claim(s) 1-12 (all claims in part), drawn to compositions comprising ansamycins.

**Group (3)**, claim(s) 1-12 (all claims in part), drawn to compositions comprising radicicolos.

**Group (4)**, claim(s) 1-12 (all claims in part), drawn to compositions comprising zearalanols.

**Group (5)**, claim(s) 1-12 (all claims in part), drawn to compositions comprising ATP analogs.

**Group (6)**, claim(s) 1-12 (all claims in part), drawn to compositions comprising indoles.

**Group (7)**, claim(s) 1-12 (all claims in part), drawn to compositions comprising chalcones.

**Group (8)**, claim(s) 1-12 (all claims in part), drawn to compositions comprising benzimidazoles.

**Group (9)**, claim(s) 15 and 16 (all claims in part), drawn to a method of treating/preventing HSP90 mediated disease wherein the composition comprises purines.

**Group (10)**, claim(s) 15 and 16 (all claims in part), drawn to a method of treating/preventing HSP90 mediated disease wherein the composition comprises ansamycins.

Art Unit: 1618

**Group (11)**, claim(s) 15 and 16 (all claims in part), drawn to a method of treating/preventing HSP90 mediated disease wherein the composition comprises radicicols.

**Group (12)**, claim(s) 15 and 16 (all claims in part), drawn to a method of treating/preventing HSP90 mediated disease wherein the composition comprises zearalanols.

**Group (13)**, claim(s) 15 and 16 (all claims in part), drawn to a method of treating/preventing HSP90 mediated disease wherein the composition comprises ATP analogs.

**Group (14)**, claim(s) 15 and 16 (all claims in part), drawn to a method of treating/preventing HSP90 mediated disease wherein the composition comprises indoles.

**Group (15)**, claim(s) 15 and 16 (all claims in part), drawn to a method of treating/preventing HSP90 mediated disease wherein the composition comprises chalcones.

**Group (16)**, claim(s) 15 and 16 (all claims in part), drawn to a method of treating/preventing HSP90 mediated disease wherein the composition comprises benzimidazoles.

**Group (17)**, claim(s) 29 (in part), drawn to a method of diagnosing/monitoring the progression/regression of an HSP90 mediated disease wherein the composition comprises purines.

**Group (18)**, claim(s) 29 (in part), drawn to a method of diagnosing/monitoring the progression/regression of an HSP90 mediated disease wherein the composition comprises ansamycins..

**Group (19)**, claim(s) 29 (in part), drawn to a method of diagnosing/monitoring the progression/regression of an HSP90 mediated disease wherein the composition comprises radicicols.

**Group (20)**, claim(s) 29 (in part), drawn to a method of diagnosing/monitoring the progression/regression of an HSP90 mediated disease wherein the composition comprises zearalanols.

**Group (21)**, claim(s) 29 (in part), drawn to a method of diagnosing/monitoring the progression/regression of an HSP90 mediated disease wherein the composition comprises ATP analogs.

**Group (22)**, claim(s) 29 (in part), drawn to a method of diagnosing/monitoring the progression/regression of an HSP90 mediated disease wherein the composition comprises indoles.

**Group (23)**, claim(s) 29 (in part), drawn to a method of diagnosing/monitoring the progression/regression of an HSP90 mediated disease wherein the composition comprises chalcones.

**Group (24)**, claim(s) 29 (in part), drawn to a method of diagnosing/monitoring the progression/regression of an HSP90 mediated disease wherein the composition comprises benzimidazoles.

2. The inventions listed as Groups (1) – (24) do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the groups are directed to distinct compositions and methods of using the compositions.

## **ELECTION OF SPECIES**

3. This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows. The claims are directed to compositions wherein the composition comprises purines, ansamycins, radicicols, zearalanols, ATP analogs, indoles, chalcones, and benzimidazoles. In addition, there are claims directed to a method of treating/preventing HSP90 mediated disease whereas the compositions comprises purines, ansamycins, radicicols, zearalanols, ATP analogs, indoles, chalcones, and benzimidazoles. Also, there are claims directed to

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply

Art Unit: 1618

must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

**Note:** Applicant is respectfully requested to elect a species from within the elected group. The elected species should identify (if applicable to the elected group) a specific ligand, a specific functional moiety, and a specific HSP90 mediated disease.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

The claims are deemed to correspond to the species listed above.

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for reasons set forth above.

4. Due to the complexity of the restriction requirement, a telephone call was not made to request an oral election to the above restriction requirement.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

5. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

#### **REJOINDER PARAGRAPH**

6. The Examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder. All claims directed to a nonelected process invention must require all the limitations of an allowable product claim for that process invention to be rejoined.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product

Art Unit: 1618

claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product claims. **Failure to do so may result in a loss of the right to rejoinder.** Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

7.. Any inquiry concerning this communication or earlier communications from the examiner should be directed to D L. Jones whose telephone number is (571)272-0617.

The examiner can normally be reached on Mon.-Fri., 6:45 a.m. - 3:15 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Hartley can be reached on (571) 272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a

Application/Control Number: 10/538,687  
Art Unit: 1618

Page 8

USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/D L. Jones/  
Primary Examiner  
Art Unit 1618

December 2, 2009